1308849-93-5

Basic information

• Product Name: (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate
• CAS NO: 1308849-93-5
• Molecular Weight: 346.383
• Mol File: 1308849-93-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 479.1±30.0 °C(Predicted)
• Density: 1.273±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate(1308849-93-5)
• EPA Substance Registry System: (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate(1308849-93-5)

Safety Data

• Hazardous Substances Data: 1308849-93-5(Hazardous Substances Data)

Usage

General Description

(R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate is a chemical compound with the molecular formula C17H22N2O6. It is a morpholine derivative with a tert-butyl ester group and a dioxoisoindolin-2-ylmethyl group attached to its structure. (R)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate has potential applications in pharmaceutical and synthetic chemistry due to its unique structure and properties. It may be utilized as a building block for the synthesis of other organic compounds or as a potential drug candidate. Its specific uses and properties would need to be determined through further research and experimentation.

Upstream product

• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 606139-90-6 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}morpholine-4-carboxylate 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 1174913-80-4 tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate 
• 1308849-94-6 (R)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-95-7 (R)-tert-butyl 2-((2-amino-4-methylphenylamino)methyl)morpholine-4-carboxylate 
• 1308849-96-8 (R)-4-(1-((4-(tert-butoxycarbonyl)morpholin-2-yl)methyl)-5-methyl-1H-benzo[d]imidazol-2-yl)-3,5-difluorobenzoic acid 
• 1308849-97-9 (R)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-lH-benzo[d]imidazol-l-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 

Relevant articles and documents

COMBINATION THERAPIES FOR TREATING PAIN

This invention generally relates to a combination therapy comprising the use of a substituted benzoimidazole compound and a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, and, in particular, to the use of methyl 2-((2-(2,6-difluoro-4- (meth